Monovalent H5 vaccine
US9694067B2 · kind B2 · utility
0Cited by
0References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 12, 2014 |
| Grant date | Jul 4, 2017 |
| Priority date | — |
| Expiry date | Dec 12, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16171
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a monovalent H5N1 vaccine. More specifically, the present invention relates to the development of a monovalent H5 vaccine strain using hemagglutinin (HA) engineering to elicit cross-clade protection. The present invention also relates to an epitope-chimeric H5 and to a reverse genetics (RG) influenza virus expressing the epitope-chimeric H5.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.